News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CytomX Therapeutics, Inc. Expands Series B Financing; Canaan Partners Joins Syndicate


7/31/2012 10:00:20 AM

SAN FRANCISCO--(BUSINESS WIRE)--CytomX Therapeutics, Inc., a biotechnology company creating a new generation of highly targeted antibody therapeutics, today announced that the company has expanded its Series B financing, bringing the total size of the round to $41 million. Canaan Partners led the financing and was joined by existing investors Third Rock Ventures and the Roche Venture Fund. In conjunction with the financing, Tim Shannon, M.D., of Canaan Partners will join CytomX’s board of directors.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES